India Pharmaceutical Market reports revenue decline in March 2022
Ind-Ra expects FY22 IPM to have witnessed 15% YoY sales growth, higher than the 8%-10% observed over the past five years, aided by the base effect
Ind-Ra expects FY22 IPM to have witnessed 15% YoY sales growth, higher than the 8%-10% observed over the past five years, aided by the base effect
The hospital is committed to adding to specialised practices in the healthcare space with its pioneering effort to promote oral health awareness and tobacco addiction prevention
Tardive dyskinesia (TD) is a movement disorder that is characterized by uncontrollable, abnormal and repetitive movements of the face, torso and/or other body parts, which may be disruptive and negatively impact patients
The next-gen logistics management solutions are making the global supply chains more customer-centric and sustainable
First PARP inhibitor to demonstrate overall survival benefit in early breast cancer
The USFDA has granted a qualified infectious disease product (QIDP) designation to WCK 6777, which signifies its ability to meet unmet medical needs and facilitates a faster approval process
Machine learning approach to systems biology combined with ligand discovery platform
The open-label, multicenter, randomized Phase 1 trial is designed to evaluate the safety and immunogenicity of experimental HIV trimer mRNA vaccines
Lynparza is approved in the US, EU, Japan and several other countries for the treatment of patients with gBRCAm, HER2-negative, metastatic breast cancer previously treated with chemotherapy based on results from the OlympiAD Phase III trial
Large players are adequately capitalised to make bigger investments to adjust for the ongoing fundamental shift in market opportunities
Subscribe To Our Newsletter & Stay Updated